Idarubicin Hydrochloride interactions

Checked as Idarubicin in this data source.

Full monograph for Idarubicin Hydrochloride Check it against another medicine

Medicines

281 documented

Severity

Mechanism

Medicines documented to interact with Idarubicin Hydrochloride, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Adalimumab	Major	Synergy	The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…	6 sources — open the full entry
Amiodarone Hydrochloride	Major	Synergy	Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related…	45 sources — open the full entry
Amisulpride	Major	Synergy	Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the…	3 sources — open the full entry
Arsenic Trioxide	Major	Synergy	Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the…	4 sources — open the full entry
Artemether + Lumefantrine	Major	Synergy	Artemether-lumefantrine may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…2 documented mechanisms	16 sources — open the full entry
Baricitinib	Major	Synergy	Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies…	4 sources — open the full entry
Bevacizumab	Major	Synergy	Coadministration of bevacizumab and anthracyclines may increase the risk of cardiac dysfunction. Bevacizumab and anthracyclines are individually cardiotoxic…	3 sources — open the full entry
Cabozantinib	Major	Synergy	Cabozantinib can cause prolongation of the QT interval.	7 sources — open the full entry
Ceritinib	Major	Synergy	Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval…	9 sources — open the full entry
Chloroquine Phosphate	Major	Synergy	Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong…	22 sources — open the full entry
Citalopram Hydrobromide	Major	Synergy	Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	15 sources — open the full entry
Clozapine	Major	Synergy	Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity…	6 sources — open the full entry
Crizotinib	Major	Synergy	Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT…	6 sources — open the full entry
Deferiprone	Major	Synergy	Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity…	5 sources — open the full entry
Efavirenz	Major	Metabolism	Efavirenz can cause significant QT interval prolongation in patients with the CYP450 2B6 6/6 genotype due to reduced metabolic clearance of the drug stemming…	6 sources — open the full entry
Escitalopram Oxalate	Major	Synergy	Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	13 sources — open the full entry
Etanercept	Major	Synergy	The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…	6 sources — open the full entry
Gatifloxacin	Major	Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…	28 sources — open the full entry
Gatifloxacin + Dexamethasone	Major	Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…	28 sources — open the full entry
Golimumab	Major	Synergy	The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…	6 sources — open the full entry
Haloperidol	Major	Synergy	Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	14 sources — open the full entry
Hydroxychloroquine Sulphate	Major	Synergy	Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong…	22 sources — open the full entry
Iloperidone	Major	Synergy	Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	9 sources — open the full entry
Infliximab	Major	Synergy	The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…	6 sources — open the full entry
Ivabradine	Major	Synergy	Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong…	10 sources — open the full entry
Ivosidenib	Major	Synergy	Ivosidenib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive…	6 sources — open the full entry
Lefamulin Acetate	Major	Synergy	Lefamulin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result…	6 sources — open the full entry
Leflunomide	Major	Synergy	The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to…	2 sources — open the full entry
Loteprednol Etabonate + Gatifloxacin	Major	Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…	28 sources — open the full entry
Mifepristone	Major	Synergy	Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may…	10 sources — open the full entry
Mifepristone + Misoprostol	Major	Synergy	Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may…	10 sources — open the full entry
Moxifloxacin HydrochlorideInjection Ophthalmic Tablet	Major	Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…	28 sources — open the full entry
Moxifloxacin Hydrochloride + Dexamethasone	Major	Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…	28 sources — open the full entry
Moxifloxacin Hydrochloride + Xanthan Gum	Major	Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…	28 sources — open the full entry
Nilotinib	Major	Synergy	Nilotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval…	9 sources — open the full entry
Osimertinib	Major	Synergy	Osimertinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	5 sources — open the full entry
Pertuzumab + Trastuzumab	Major	Synergy	The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline…	5 sources — open the full entry
Ribociclib	Major	Synergy	Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	16 sources — open the full entry
Rotavirus Vaccine	Major	Others	The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…	9 sources — open the full entry
Selpercatinib	Major	Synergy	Selpercatinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT…	6 sources — open the full entry
Sotalol Hydrochloride	Major	Synergy	Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related…	45 sources — open the full entry
Sparfloxacin	Major	Synergy	Sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT…	21 sources — open the full entry
Thalidomide	Major	Synergy	Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism…	20 sources — open the full entry
Tofacitinib	Major	Others	Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies…	1 sources — open the full entry
Trastuzumab	Major	Synergy	The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline…	5 sources — open the full entry
Upadacitinib	Major	Others	Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.	1 sources — open the full entry
Yellow Fever Vaccine	Major	Others	The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms	19 sources — open the full entry
Ziprasidone	Major	Synergy	Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	10 sources — open the full entry
Abiraterone Acetate	Moderate	Absorption	Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates…	5 sources — open the full entry
Aclidinium Bromide + Formoterol Fumarate	Moderate	Synergy	Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that…	30 sources — open the full entry

Conditions

Conditions in which Idarubicin Hydrochloride needs care, as documented in this source.

Bone Marrow Failure Disorders
Major
Idarubicin induces severe myelosuppression at therapeutic doses. Therapy with idarubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. If the need outweighs the risk, extreme caution should be exercised in administering idarubicin. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended.
11 sources
1. Elbaek K, Ebbehoj E, Jakobsen A, Juul P, Rasmussen SN, Bastholt L, Dalmark M, Steiness E, Ebbehj E "Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects." Clin Pharmacol Ther 45 (1989): 627-34
2. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al. "Phase I and II clinical and pharmacological study of 4- demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia." Cancer Res 45 (1985): 1408-12
3. Krarup-Hansen A, Andersen E, Elbaek K, Rasmussen SN, Dalmark M "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer." Acta Oncol 27 (1988): 521-5
4. Case DC Jr, Gerber MC, Gams RA, Crawford J, Votaw ML, Higano CS, Pruitt BT, Gould J "Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma." Cancer Res 52 (1992): 3871-4
5. Chevallier B, Monnier A, Metz R, Namer M, Marty M, Roche H, Bastit P, Hurteloup P "Phase II study of oral idarubicin in elderly patients with advanced breast cancer." Am J Clin Oncol 13 (1990): 436-9
6. van Eys J, Steuber P, Haggard ME, Sabio H, Duncan M "Trial of daunomycin in acute promyelocytic leukemia of childhood: a Southwest Oncology Group Study." Am J Pediatr Hematol Oncol 3 (1981): 301-3
7. Gillies H, Liang R, Rogers H, Harper P, Parapia L, Cox G, Johnson S "Phase II trial of idarubicin in patients with advanced lymphoma." Cancer Chemother Pharmacol 21 (1988): 261-4
8. Milroy R, Cummings J, Kaye SB, Banham SW "Phase II clinical and pharmacological study of oral 4- demethoxydaunorubicin in advanced non-pretreated small cell lung cancer." Cancer Chemother Pharmacol 20 (1987): 75-7
Show all 11 sourcesShow fewer sources
1. Ganzina F, Pacciarini MA, Di Pietro N "Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies." Invest New Drugs 4 (1986): 85-105
2. Petti MC, Mandelli F "Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA." Semin Oncol 16 (1 Suppl) (1989): 10-5
3. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn (2001):
Heart Diseases
Major
Idarubicin can cause myocardial toxicity leading to congestive heart failure. Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure. Close clinical monitoring of cardiac function, such as an electrocardiogram and/or determination of left ventricular ejection fraction, prior to each course of therapy is recommended.
5 sources
1. Chan-Lam D, Copplestone JA, Prentice A, Price R, Johnson S, Phillips M "Idarubicin cardiotoxicity in acute myeloid leukaemia." Lancet 340 (1992): 185-6
2. Bertelli G, Amoroso D, Pronzato P, Rosso R "Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors." Anticancer Res 8 (1988): 645-6
3. Villani F, Galimberti M, Comazzi R, Crippa F "Evaluation of cardiac toxicity of idarubicin (4- demethoxydaunorubicin)." Eur J Cancer Clin Oncol 25 (1989): 13-8
4. Gillies H, Liang R, Rogers H, Harper P, Parapia L, Cox G, Johnson S "Phase II trial of idarubicin in patients with advanced lymphoma." Cancer Chemother Pharmacol 21 (1988): 261-4
5. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn (2001):
Infections
Major
Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.
39 sources
1. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
2. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories (2002):
3. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb (2001):
4. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb (2001):
5. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation (2001):
6. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb (2001):
7. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb (2001):
8. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) (2001):
Show all 39 sourcesShow fewer sources
1. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
2. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
3. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
4. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
5. "Product Information. Fludara (fludarabine)." Berlex Laboratories (2001):
6. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn (2001):
7. "Product Information. Matulane (procarbazine)." Roche Laboratories (2001):
8. "Product Information. DTIC-Dome (dacarbazine)." Bayer (2001):
9. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn (2001):
10. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc (2001):
11. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company (2001):
12. "Product Information. Hycamtin (topotecan)." SmithKline Beecham (2001):
13. "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer (2001):
14. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb (2001):
15. "Product Information. Nipent (pentostatin)." Hospira Inc (2001):
16. "Product Information. Tabloid (thioguanine)." Prasco Laboratories (2001):
17. "Product Information. Xeloda (capecitabine)." Roche Laboratories (2001):
18. "Product Information. Alkeran (melphalan)." Glaxo Wellcome (2022):
19. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome (2001):
20. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
21. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc (2001):
22. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn (2001):
23. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation (2001):
24. "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
25. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
26. "Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc (2014):
27. "Product Information. Blincyto (blinatumomab)." Amgen USA (2014):
28. "Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb (2014):
29. "Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation (2015):
30. "Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb (2015):
31. "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
Kidney Diseases
Major
Impaired renal function can affect the disposition of idarubicin. Therapy with idarubicin should be administered cautiously and dosage modification considered in patients with compromised renal function. Clinical monitoring of renal function is recommended prior to and during therapy.
1 source
1. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn (2001):
Liver Diseases
Major
Idarubicin undergoes extensive extrahepatic metabolism and is primarily eliminated by biliary excretion. The pharmacokinetic disposition of idarubicin has not been studied in leukemia patients with hepatic impairment. It is thought that the metabolism of idarubicin would be decreased in moderate to severe hepatic dysfunction and lead to increased systemic drug levels and toxicity. Therapy with idarubicin should be administered cautiously and dosage reduction considered in patients with compromised hepatic function. Idarubicin injection should not be administered if bilirubin level exceeds 5 mg %. Clinical monitoring of hepatic function is recommended prior to and during therapy.
7 sources
1. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al. "Phase I and II clinical and pharmacological study of 4- demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia." Cancer Res 45 (1985): 1408-12
2. Krarup-Hansen A, Andersen E, Elbaek K, Rasmussen SN, Dalmark M "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer." Acta Oncol 27 (1988): 521-5
3. Lowenthal RM, Chesterman CN, Griffiths JD, Manoharan A, Harris MG, Herrmann RP, Rooney KF, Rozenberg MC, Salem HH, Wolf MM, et al. "Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients." Cancer Treat Rep 71 (1987): 1279-81
4. Chisesi T, Capnist G, de Dominicis E, Dini E "A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma." Eur J Cancer Clin Oncol 24 (1988): 681-4
5. Dodion P, Finet C, Crespeigne N, Beer M, Nicaise C, Rozencweig M, Kenis Y "Phase I study of oral idarubicin given with a weekly schedule." Invest New Drugs 4 (1986): 31-8
6. Petti MC, Mandelli F "Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA." Semin Oncol 16 (1 Suppl) (1989): 10-5
7. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn (2001):
Hyperuricemia
Moderate
Treatment with idarubicin may cause hyperuricemia as a result of rapid lysis of tumor cells. Levels of serum uric acid should be monitored and appropriate therapy should be initiated before starting therapy.
1 source
1. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn (2001):

Therapeutic duplication

Drug classes that overlap with Idarubicin Hydrochloride, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

antineoplastic antibiotics
The recommended maximum number of medicines in the 'antineoplastic antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antineoplastic antibiotics' category.
Example product in the source data (US market): Vyxeos

Medicines

Conditions

Bone Marrow Failure Disorders

Heart Diseases

Infections

Kidney Diseases

Liver Diseases

Hyperuricemia

Therapeutic duplication

antineoplastic antibiotics